Caribou Biosciences Q2 FY26 GAAP net loss narrows to USD 24.3 million; revenue falls to USD 1.5 million
CRBU•Caribou Biosciences reports Q2 FY26 results
- Caribou Biosciences posted a GAAP net loss of USD 24.3 million, or USD 0.24 per share, in Q2 2026.
- Loss narrowed from USD 54.1 million, or USD 0.58 per share, a year earlier, which included USD 21.3 million in non-cash impairment.
- Revenue fell 43.8% to USD 1.5 million versus Q2 2025.
- R&D expenses dropped 31.6% to USD 18.9 million, due to lower external CMO/CRO activity and prior workforce reduction.
- Cash, cash equivalents and marketable securities totaled USD 113.8 million; runway expected to extend to end-2027, with funding options explored for ANTLER-3.**
